MedPath

AstraZeneca

AstraZeneca logo
🇬🇧United Kingdom
Ownership
Public
Employees
89.9K
Market Cap
$270.3B
Website
http://www.astrazeneca.co.uk
Introduction

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Retrospective Treatment Pattern Survey for the Patients With Hypertension and Stroke

Completed
Conditions
Hypertension
First Posted Date
2008-05-21
Last Posted Date
2009-07-09
Lead Sponsor
AstraZeneca
Target Recruit Count
1000
Registration Number
NCT00681707
Locations
🇰🇷

Research Site, Seoul, Korea, Republic of

Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer

Phase 1
Completed
Conditions
Head and Neck Cancer
Interventions
First Posted Date
2008-05-21
Last Posted Date
2010-09-23
Lead Sponsor
AstraZeneca
Target Recruit Count
30
Registration Number
NCT00681967
Locations
🇨🇭

Research Site, Bern, Switzerland

Asthma Patient Survey Study to Assess Asthma Effect and Medication in Finland

Completed
Conditions
Asthma
First Posted Date
2008-05-21
Last Posted Date
2011-01-24
Lead Sponsor
AstraZeneca
Target Recruit Count
142
Registration Number
NCT00681382

Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France

Completed
Conditions
Breast Cancer
First Posted Date
2008-05-21
Last Posted Date
2011-01-24
Lead Sponsor
AstraZeneca
Target Recruit Count
217
Registration Number
NCT00681369

Quetiapine in Postpartum Depression

Phase 2
Terminated
Conditions
Postpartum Depressive Disorder
Interventions
First Posted Date
2008-05-21
Last Posted Date
2010-12-21
Lead Sponsor
AstraZeneca
Target Recruit Count
5
Registration Number
NCT00681668
Locations
🇩🇪

Research Site, Herten, Westfalen-Lippe, Germany

Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280

Phase 1
Completed
Conditions
Anxiety
Interventions
First Posted Date
2008-05-21
Last Posted Date
2010-12-10
Lead Sponsor
AstraZeneca
Target Recruit Count
8
Registration Number
NCT00681746
Locations
🇸🇪

Research Site, Stockholm, Sweden

AZD6280 Multiple Ascending Dose Study

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
First Posted Date
2008-05-21
Last Posted Date
2010-12-09
Lead Sponsor
AstraZeneca
Target Recruit Count
48
Registration Number
NCT00681317
Locations
🇺🇸

Research Site, Philadelphia, Pennsylvania, United States

AZD7325 Multiple Ascending Dose Study

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
First Posted Date
2008-05-21
Last Posted Date
2010-12-09
Lead Sponsor
AstraZeneca
Target Recruit Count
48
Registration Number
NCT00681915
Locations
🇺🇸

Research Site, Philadelphia, Pennsylvania, United States

Retrospective Survey for Patients With Hypertension and Diabetes Mellitus

Completed
Conditions
Hypertension
First Posted Date
2008-05-21
Last Posted Date
2010-12-02
Lead Sponsor
AstraZeneca
Target Recruit Count
2000
Registration Number
NCT00681278
Locations
🇰🇷

Research Site, Wonju, Korea, Republic of

OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.

Completed
Conditions
Diabetes
First Posted Date
2008-05-21
Last Posted Date
2020-01-22
Lead Sponsor
AstraZeneca
Target Recruit Count
4027
Registration Number
NCT00681850
Locations
🇬🇧

Research Site, Westbury, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath